SVRA
Savara Inc
$6.22
+0.16 (+2.64%)
At close · Jul 2
Market Cap
$1.27B
Shares
204,927,212
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.22
Open$6.10
Day$6.07–6.26
52W$2.03–7.01
Avg vol 30d1.7M
Short int31.4M · 15.3% float · 19.3d
Short vol73%
Last earningsAug 6, 2020
DataJan 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+20% above
+
Price vs 50-day avg
+17% above
◦
RSI (14)
70 · neutral
+
MACD trend
positive
◦
52-week position
84% · mid-range
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $5 › 200d $5 — 50d above 200d
+
Institutional flow
+26% holders QoQ · +61 funds added
−
Insider flow
Net -$2.2M over 90 days · 100% sells
−
Short interest
15.30% of float · ▲ +3.9% MoM · 19.3 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
185 holders — near 3-yr high, broad support
Fundamentals
Weak
−
Revenue growth
−100% Y/Y
−
EPS growth
−10% Y/Y
−
Free cash flow
$-101.1M
+
Balance sheet
net cash $3.3M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+20% above
Bullish
Price vs 50-day avg
+17% above
Bullish
RSI (14)
70 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
84% · mid-range
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +61 funds added
Insider flow
Distributing
Net -$2.2M over 90 days · 100% sells
Short interest
Rising
15.30% of float · ▲ +3.9% MoM · 19.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
185 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $6 · 84%
52-wk high $7
vs 200-day avg +20%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SVRA
this stock
Savara Inc
|
$1.27B | +3.2% | -100.0% | — | 15.3% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SVRA | +3.2% | +18.5% | +8.0% | +1.0% | +3.2% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +1.7% | +19.7% | 0.0% | +1.2% | -6.1% |